GatePass Capital’s GoodRx Holdings GDRX Stock Holding History

GatePass Capital’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$42.3K	–	165
2025 Q3	$42.3K	Hold	10,000	–	–	0.02%	144
2025 Q2	$49.8K	Hold	10,000	–	–	0.03%	126
2025 Q1	$44.1K	Hold	10,000	–	–	0.03%	113
2024 Q4	$46.5K	Buy	+10,000	New	+$55K	0.05%	104

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PTC

Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

GatePass Capital's GDRX Position: Q4 2025 in Review

GatePass Capital sold out of GoodRx Holdings (GDRX) in Q4 2025, closing a stake of 10,000 shares — an estimated $42.3K sold.

GatePass Capital first reported a position in GDRX in Q4 2024 and held it in 4 quarters. The position peaked at $49.8K in Q2 2025. 183 funds tracked by Wall St. Rank hold GDRX as of Q4 2025.

GatePass Capital reported no remaining GoodRx Holdings position as of Q4 2025 after selling out during the quarter.
GatePass Capital sold 10,000 GoodRx Holdings shares in Q4 2025, an estimated $42.3K.
GatePass Capital first reported a position in GoodRx Holdings in Q4 2024 and held it in 4 quarters.
GatePass Capital's GoodRx Holdings position peaked at $49.8K in Q2 2025.
183 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2025.

Based on GatePass Capital's 13F filing for Q4 2025, filed 9 Feb 2026.